Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-01-30$65.53/sh−971$63,630→ 57,208 total - Sale
Common Stock
2024-01-29$64.14/sh−279$17,895→ 58,179 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024.
- [F2]This is a scheduled sale from an established 10b5-1 plan.